Pliant Therapeutics Inc logo

PLRX

Pliant Therapeutics Inc

$19.98

Earnings Summary

Revenue
$1.25Mn
Net Profits
$-28.1Mn
Net Profit Margins
-2249.8%

Highlights

Revenue:

Pliant Therapeutics Inc’s revenue fell -42.55% since last year same period to $1.25Mn in the Q1 2022. On a quarterly growth basis, Pliant Therapeutics Inc has generated -37.52% fall in its revenue since last 3-months.

Net Profits:

Pliant Therapeutics Inc’s net profit fell -22.94% since last year same period to $-28.1Mn in the Q1 2022. On a quarterly growth basis, Pliant Therapeutics Inc has generated -14.55% fall in its net profits since last 3-months.

Net Profit Margins:

Pliant Therapeutics Inc’s net profit margin fell -113.99% since last year same period to -2249.8% in the Q1 2022. On a quarterly growth basis, Pliant Therapeutics Inc has generated -83.33% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Pliant Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.81
EPS Estimate Current Year
-0.81

Highlights

EPS Estimate Current Quarter:

Pliant Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a -8% fall from last quarter’s estimates.

EPS Estimate Current Year:

Pliant Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.81.

Key Ratios

Key ratios of the Pliant Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.78
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-0.56
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Pliant Therapeutics Inc’s earning per share (EPS) fell -21.88% since last year same period to -0.78 in the Q1 2022. This indicates that the Pliant Therapeutics Inc has generated -21.88% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Pliant Therapeutics Inc’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Pliant Therapeutics Inc’s return on equity (ROE) stands at -0.56.

Dividend Per Share (DPS):

Pliant Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.75
-0.78
-4%

Company Information

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Organisation
Pliant Therapeutics Inc
Headquarters
South San Francisco, California, US
Employees
78
Industry
Health Technology
CEO
Bernard Coulie